Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 20/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 18/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 16/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.74 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.61 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3199720 | 0.92 | PIK3CB (0.85) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752192 | 0.90 | PIK3CB (0.81) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL3218899 | 0.88 | PIK3CB (0.78) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752187 | 0.88 | PIK3CB (0.78) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752189 | 0.88 | PIK3CB (0.78) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752209 | 0.87 | PIK3CB (0.77) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL13752207 | 0.87 | PIK3CB (0.77) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL3209521 | 0.85 | PIK3CB (0.83) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 | |
| SCHEMBL3206304 | 0.85 | PIK3CD (1.00) | PIK3CBPIK3CDPIK3CAPIK3CG | |
| SCHEMBL13752219 | 0.84 | PIK3CB (0.84) | PIK3CBPIK3CDPIK3CAPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029693-A1 | NOVEL PI3K DELTA INHIBITORS AND METHODS OF USE THEREOF | ICOS CORPORATION | 2010-02-04 | — | — | US | disclosed |
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | disclosed |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | ICOS CORPORATION | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054614-A1 | Methods of inhibiting leukocyte accumulation | PI4KB, PIK3CD, PIK3CA | PIK3CB 4/4885PIK3CD 2/4885PIK3CA 3/4885 |
| US-20050043239-A1 | Methods of inhibiting immune responses stimulated by an endogenous factor | PI4KB, PI4KA, PIK3CD | PIK3CB 6/4885PIK3CD 3/4885PIK3CA 12/4885 |
| US-20100029693-A1 | NOVEL PI3K DELTA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CA, PIK3R5 | PIK3CB 7/4885PIK3CD 1/4885PIK3CA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.